MEP16308A - Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika - Google Patents

Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika

Info

Publication number: MEP16308A
Authority: ME; Montenegro
Prior art keywords: docetaxel; cyclophosphamide; doxorubicin; ovarian cancer; adjuvant therapy
Prior art date: 2002-05-17

Application number

MEP-163/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Hichem Chakroun

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-17

Filing date

2003-05-15

Publication date

2010-06-10

2003-05-15 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2010-06-10 Publication of MEP16308A publication Critical patent/MEP16308A/hr

Links

AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 title abstract 4
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 title abstract 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title abstract 2
206010033128 Ovarian cancer Diseases 0.000 title abstract 2
206010061535 Ovarian neoplasm Diseases 0.000 title abstract 2
238000009098 adjuvant therapy Methods 0.000 title abstract 2
229960004397 cyclophosphamide Drugs 0.000 title abstract 2
229960003668 docetaxel Drugs 0.000 title abstract 2
229960004679 doxorubicin Drugs 0.000 title abstract 2
206010006187 Breast cancer Diseases 0.000 title 1
208000026310 Breast neoplasm Diseases 0.000 title 1
210000000481 breast Anatomy 0.000 title 1
206010055113 Breast cancer metastatic Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MEP-163/08A 2002-05-17 2003-05-15 Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika MEP16308A (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38085002P	2002-05-17	2002-05-17
PCT/EP2003/007443 WO2003097164A1 (en)	2002-05-17	2003-05-15	Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
YU96304A RS96304A (en)	2002-05-17	2003-05-15	Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer

Publications (1)

Publication Number	Publication Date
MEP16308A true MEP16308A (hr)	2010-06-10

Family

ID=29550025

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MEP-2008-163A ME00055B (me)	2002-05-17	2003-05-15	Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika
MEP-163/08A MEP16308A (hr)	2002-05-17	2003-05-15	Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MEP-2008-163A ME00055B (me)	2002-05-17	2003-05-15	Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika

Country Status (28)

Country	Link
US (2)	US20040014694A1 (hr)
EP (1)	EP1507573A1 (hr)
JP (1)	JP4773719B2 (hr)
KR (1)	KR20050000544A (hr)
CN (1)	CN1652845A (hr)
AU (1)	AU2003244646B2 (hr)
BR (1)	BR0310026A (hr)
CA (1)	CA2486124A1 (hr)
CR (1)	CR7575A (hr)
EC (1)	ECSP045433A (hr)
HR (1)	HRPK20041072B3 (hr)
IL (1)	IL165214A0 (hr)
MA (1)	MA27417A1 (hr)
ME (2)	ME00055B (hr)
MX (1)	MXPA04010640A (hr)
MY (1)	MY146533A (hr)
NO (1)	NO20045370L (hr)
NZ (1)	NZ535992A (hr)
OA (1)	OA12819A (hr)
PA (1)	PA8574001A1 (hr)
RS (1)	RS96304A (hr)
RU (1)	RU2321396C2 (hr)
TN (1)	TNSN04217A1 (hr)
TW (1)	TWI374741B (hr)
UA (1)	UA81628C2 (hr)
UY (1)	UY27812A1 (hr)
WO (1)	WO2003097164A1 (hr)
ZA (1)	ZA200408549B (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE471740T1 (de) *	2003-09-25	2010-07-15	Astellas Pharma Inc	Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
RU2265440C2 (ru) *	2004-01-13	2005-12-10	Ростовский научно-исследовательский онкологический институт МЗ РФ	Способ предоперационного лечения рака молочной железы
JP2006316040A (ja)	2005-05-13	2006-11-24	Genentech Inc	Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7776832B2 (en) *	2006-04-21	2010-08-17	Gem Pharmaceuticals, Llc	Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
WO2008027988A2 (en) *	2006-08-31	2008-03-06	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
AU2012235902B2 (en)	2011-04-01	2015-08-27	Astrazeneca Ab	Therapeutic treatment
SG11201401471PA (en)	2011-11-30	2014-08-28	Astrazeneca Ab	Combination treatment of cancer
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
WO2014169067A1 (en) *	2013-04-09	2014-10-16	Merrimack Pharmaceuticals, Inc.	Compositions for improving outcomes of liposomal chemotherapy
RU2020120593A (ru) *	2014-04-25	2020-09-01	Дженентек, Инк.	Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
US10849916B2 (en)	2014-07-11	2020-12-01	Dr. Reddys Laboratories Limited	Stable liquid formulations of cyclophosphamide and its impurities
WO2016005962A2 (en)	2014-07-11	2016-01-14	Dr. Reddy’S Laboratories Limited	Stable liquid formulations of cyclophosphamide and processes
SG11201707127VA (en)	2015-03-06	2017-09-28	Beyondspring Pharmaceuticals Inc	Method of treating cancer associated with a ras mutation
MY181892A (en)	2015-07-13	2021-01-12	Beyondspring Pharmaceuticals Inc	Plinabulin compositions
EP3366296B1 (en) *	2015-10-22	2020-01-15	Universidade De Santiago De Compostela	Methods for using regulators for increasing the expression or activation of p53 and/or regulators for reducing or inhibiting the expression of p63-alpha, for the treatment of non-alcoholic fatty liver disease (nafld) and/or non-alcoholic steatohepatitis (nash)
WO2017139231A1 (en)	2016-02-08	2017-08-17	Beyondspring Pharmaceuticals, Inc.	Compositions containing tucaresol or its analogs
US20190177430A1 (en) *	2016-08-24	2019-06-13	The Wistar Institute Of Anatomy And Biology	Methods of Treating Cancers With Chemotherapy With Reduced Toxicity
US11491147B2 (en) *	2016-10-03	2022-11-08	Indiana University Research And Technology Corporation	Combination drug therapy reduces PARP-1 related DNA repair and increases the efficacy of genotoxic agents
US11633393B2 (en)	2017-01-06	2023-04-25	Beyondspring Pharmaceuticals, Inc.	Tubulin binding compounds and therapeutic use thereof
IL268305B2 (en)	2017-02-01	2024-08-01	Beyondspring Pharmaceuticals Inc	Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
HRP20240069T1 (hr)	2017-03-02	2024-03-29	Genentech, Inc.	Adjuvantno liječenje her2-pozitivnog raka dojke
JP7350015B2 (ja)	2018-01-24	2023-09-25	ビヨンドスプリングファーマシューティカルズ，インコーポレイテッド	プリナブリンの投与による血小板減少症を軽減するための組成物および方法
SG11202012029PA (en)	2018-06-22	2021-01-28	Ohio State Innovation Foundation	Methods and compositions for inhibition of dihydroorotate dehydrogenase
CN115969792A (zh) *	2023-01-29	2023-04-18	常州金远药业制造有限公司	一种紫杉烷类药物与环磷酰胺共载载药脂质体制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es)	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US6441026B1 (en) *	1993-11-08	2002-08-27	Aventis Pharma S.A.	Antitumor compositions containing taxane derivatives
US5565478A (en) *	1994-03-14	1996-10-15	The United States Of America As Represented By The Department Of Health & Human Services	Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US6262054B1 (en) *	1996-02-01	2001-07-17	Sloan-Kettering Institute Of Cancer Research	Combination therapy method for treating breast cancer using edatrexate
US6323205B1 (en) *	1996-07-17	2001-11-27	Sloan-Kettering Institute For Cancer Research	Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
US6541508B2 (en) *	1999-09-13	2003-04-01	Nobex Corporation	Taxane prodrugs
TWI310684B (en) *	2000-03-27	2009-06-11	Bristol Myers Squibb Co	Synergistic pharmaceutical kits for treating cancer
US20020128228A1 (en) *	2000-12-01	2002-09-12	Wen-Jen Hwu	Compositions and methods for the treatment of cancer

2003
- 2003-05-15 ME MEP-2008-163A patent/ME00055B/me unknown
- 2003-05-15 WO PCT/EP2003/007443 patent/WO2003097164A1/en active Application Filing
- 2003-05-15 MX MXPA04010640A patent/MXPA04010640A/es active IP Right Grant
- 2003-05-15 EP EP03738122A patent/EP1507573A1/en not_active Withdrawn
- 2003-05-15 KR KR10-2004-7018431A patent/KR20050000544A/ko not_active Withdrawn
- 2003-05-15 OA OA1200400307A patent/OA12819A/en unknown
- 2003-05-15 CA CA002486124A patent/CA2486124A1/en not_active Abandoned
- 2003-05-15 JP JP2004505157A patent/JP4773719B2/ja not_active Expired - Fee Related
- 2003-05-15 NZ NZ535992A patent/NZ535992A/en not_active IP Right Cessation
- 2003-05-15 UA UA20041210381A patent/UA81628C2/uk unknown
- 2003-05-15 CN CNA038112388A patent/CN1652845A/zh active Pending
- 2003-05-15 RS YU96304A patent/RS96304A/sr unknown
- 2003-05-15 AU AU2003244646A patent/AU2003244646B2/en not_active Ceased
- 2003-05-15 RU RU2004136984/15A patent/RU2321396C2/ru not_active IP Right Cessation
- 2003-05-15 ME MEP-163/08A patent/MEP16308A/hr unknown
- 2003-05-15 IL IL16521403A patent/IL165214A0/xx unknown
- 2003-05-15 HR HR20041072A patent/HRPK20041072B3/hr not_active IP Right Cessation
- 2003-05-15 BR BR0310026-0A patent/BR0310026A/pt not_active IP Right Cessation
- 2003-05-16 US US10/439,827 patent/US20040014694A1/en not_active Abandoned
- 2003-05-16 MY MYPI20031829A patent/MY146533A/en unknown
- 2003-05-16 UY UY27812A patent/UY27812A1/es not_active Application Discontinuation
- 2003-05-16 PA PA20038574001A patent/PA8574001A1/es unknown
- 2003-05-16 TW TW092113275A patent/TWI374741B/zh not_active IP Right Cessation
2004
- 2004-10-21 ZA ZA2004/08549A patent/ZA200408549B/en unknown
- 2004-11-03 MA MA27924A patent/MA27417A1/fr unknown
- 2004-11-11 TN TNP2004000217A patent/TNSN04217A1/en unknown
- 2004-11-16 EC EC2004005433A patent/ECSP045433A/es unknown
- 2004-11-17 CR CR7575A patent/CR7575A/es unknown
- 2004-12-08 NO NO20045370A patent/NO20045370L/no not_active Application Discontinuation
2007
- 2007-06-28 US US11/769,859 patent/US20070265213A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HRP20041072A2 (en)	2005-06-30
IL165214A0 (en)	2005-12-18
RS96304A (en)	2006-10-27
NZ535992A (en)	2008-11-28
TW200407152A (en)	2004-05-16
JP2005529925A (ja)	2005-10-06
MXPA04010640A (es)	2005-08-16
MA27417A1 (fr)	2005-07-01
US20040014694A1 (en)	2004-01-22
CN1652845A (zh)	2005-08-10
AU2003244646B2 (en)	2008-08-07
US20070265213A1 (en)	2007-11-15
UA81628C2 (uk)	2008-01-25
HRPK20041072B3 (hr)	2007-07-31
CA2486124A1 (en)	2003-11-27
BR0310026A (pt)	2005-02-15
MY146533A (en)	2012-08-15
TWI374741B (en)	2012-10-21
CR7575A (es)	2006-05-10
NO20045370L (no)	2004-12-08
ZA200408549B (en)	2006-01-25
PA8574001A1 (es)	2003-12-19
TNSN04217A1 (en)	2007-03-12
KR20050000544A (ko)	2005-01-05
RU2321396C2 (ru)	2008-04-10
EP1507573A1 (en)	2005-02-23
WO2003097164A1 (en)	2003-11-27
ECSP045433A (es)	2005-01-03
ME00055B (me)	2010-10-10
UY27812A1 (es)	2003-11-28
OA12819A (en)	2006-07-10
JP4773719B2 (ja)	2011-09-14
RU2004136984A (ru)	2005-06-27
AU2003244646A1 (en)	2003-12-02

Publication	Publication Date	Title
MEP16308A (hr)	2010-06-10	Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika
ATE312635T1 (de)	2005-12-15	Ventilanordnung
CY1105818T1 (el)	2011-02-02	Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
NO20032027L (no)	2003-07-04	Effektive antitumorbehandlinger
NO20022065L (no)	2002-06-24	Terapeutisk anvendelse
MXPA04004355A (es)	2004-08-11	Tratamiento de combinacion que comprende zd6474 y un taxano.
SE0300098D0 (sv)	2003-01-15	Use of cyclin D1 inhibitors
MXPA04001912A (es)	2004-07-23	Aminobenzofenonas novedosas.
ATE385798T1 (de)	2008-03-15	Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen
NZ527655A (en)	2006-03-31	Combination of a taxane (docetaxel) and a cyclin-dependent kinase inhibitor (flavopiridol)
ATE345805T1 (de)	2006-12-15	Calciumtrifluoracetat mit zytotoxischer wirkung
ATE527282T1 (de)	2011-10-15	Tumor assoziierte antigene
DK0455769T3 (da)	1996-02-05	Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
AU2003269621A1 (en)	2004-03-29	Neoadjuvant treatment of breast cancer
TH102680A (th)	2010-07-29	การใช้โดซีแทกเซล/ดอกโซรูบิซิน/ไซโคลฟอสฟาไมด์ ในการรักษาแบบเสริม
UA40393A (uk)	2001-07-16	Спосіб лікування хронічного обструктивного бронхіту
NO20051601L (no)	2005-04-22	Kombinasjonsterapi med gemcitabin og zd6126
NO20043774L (no)	2005-01-06	The use of devazenide as analgesic agent
AR039862A1 (es)	2005-03-02	Uso de fexofenadina para la fabricacion de un medicamento para tratar un asma
RU2001129201A (ru)	2003-07-10	Способ лечения хронического травматического остеомиелита, осложненного гнойно-воспалительным процессом в околочелюстных мягких тканях
MY128724A (en)	2007-02-28	Liver selective theraphy.
EA200600987A1 (ru)	2006-10-27	Применение сирамезина в лечении злокачественных опухолей